Hormone therapy for prostate cancer a tricky choice
Hormone therapy for prostate cancer can go either way, while some patents withstand the therapy, others outwit a standard hormone therapy, causing cancer to spread. A recent study explores the reason behind this. The research also points to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. The study also explores how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. The findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Prostate cancer is the second-leading cause of cancer death in men, behind lung cancer, killing nearly 30,000 in the U.S. each year, according to the American Cancer Society. In its early stag s, the most common type, adenocarcinoma, is curable and generall ey responds well to therapies, including those that target androgen (a male sex hormone that stimulates